Literature DB >> 25593342

CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.

John Mendelsohn1, Marie Prewett2, Patricia Rockwell3, Neil I Goldstein4.   

Abstract

Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25593342     DOI： 10.1158/1078-0432.CCR-14-2491

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

2.  John Mendelsohn's journey in cancer biology and therapy.

Authors:  Rakesh Kumar
Journal:  Cancer Biol Ther       Date:  2020-01-23       Impact factor: 4.742

3.  SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway.

Authors:  Haitao Guan; Ping Zhao; Zhijun Dai; Xiaoxu Liu; Xijing Wang
Journal:  Tumour Biol       Date:  2016-05-24

4.  GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Authors:  Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-02-02

Review 5.  Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Authors:  Teresa Troiani; Stefania Napolitano; Carminia Maria Della Corte; Giulia Martini; Erika Martinelli; Floriana Morgillo; Fortunato Ciardiello
Journal:  ESMO Open       Date:  2016-09-16

6.  Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab.

Authors:  Man Xing; Xiang Wang; Yudan Chi; Dongming Zhou
Journal:  Oncotarget       Date:  2016-05-10

Review 7.  From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science.

Authors:  Jau-Song Yu
Journal:  Biomed J       Date:  2019-04-30       Impact factor: 4.910

Review 8.  EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?

Authors:  Mario Cioce; Vito Michele Fazio
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

Review 9.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

10.  John Mendelsohn: A visionary scientist, oncologist and leader.

Authors:  Rakesh Kumar; Ferid Murad; Oliver Bogler; Bert W O'Malley; Gabriel N Hortobagyi
Journal:  Genes Cancer       Date:  2019
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.